Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 21Neoplasms 6Neoplasm Metastasis 5Ovarian Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hereditary Sensory and Autonomic Neuropathies 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Refractory to Standard Therapy 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma 1Recurrence 1Rare Tumor 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1

Interventions

pembrolizumab 2toripalimab 1tislelizumab 1spartalizumab 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1lenvatinib 1atezolizumab 1amivantamab 1Tiragolumab 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor, Adult × palbociclib × Clear all
NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Tianjin Medical University Second Hospital

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡